Tempest Therapeutics, Inc. (TPST) News
Track canonical SquawkNews coverage tagged to TPST, Tempest Therapeutics, Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 16 indexed stories across 9 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
Tempest Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Ratings actions from Benzinga: GMT) Tempest Therapeutics Price Target Cut to $7.00/Share From $11.00 by HC Wainwright & Co.Ratings actions from Benzinga
NEWS | Sep 24, 2026, 04:06 PM UTC
L
Tempest Appoints Nancy Freda-Smith to Bd of Directors
Tempest Appoints Nancy Freda-Smith to Bd of Directors
NEWS | Sep 23, 2026, 12:18 PM UTC
L
Tempest Therapeutics, Inc. (TPST) Names Nancy Freda-Smith to Board, Chairs Audit
Tempest Therapeutics appointed Nancy Freda-Smith to its board of directors and named her Chair of the Audit Committee.Material DetailsContext by AI AnalystThis is an early-stage governance move for a clinical biotech aim
NEWS | Sep 23, 2026, 12:03 PM UTC
L
Tempest Appoints Global Finance Leader Nancy Freda-Smith to Board of Directors
Accomplished finance and enterprise executive with over 20 years of global leadership in multinational and Fortune 500 companiesBRISBANE, Calif., Sept. 23, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. NASDAQ:TPST
NEWS | Sep 23, 2026, 12:03 PM UTC
L
TPST - Tempest Appoints Global Finance Leader Nancy Freda-Smith to Board of Directors
TPST - Tempest Appoints Global Finance Leader Nancy Freda-Smith to Board of Directors
NEWS | Sep 23, 2026, 12:00 PM UTC
M
Tempest Therapeutics jumps after-hours on Hebei Senlang option deal
Tempest Therapeutics (TPST) rose about 66% after-hours to $1.26 following an exclusive option deal with Hebei Senlang. The company said its dose-escalation trial showed no Grade 3+ cytokine release syndrome or ICANS as o
EQUITY | Sep 21, 2026, 11:28 AM UTC
M
Tempest Therapeutics raises about $2.5M in private placement
Tempest Therapeutics completed a private placement raising approximately $2.5 million via pre-funded warrants bundled with Series C and Series D common warrants, with additional potential proceeds of about $5 million upo
EQUITY | Sep 15, 2026, 08:14 PM UTC
L
TPST - Tempest Secures Exclusive Option to License Clinical -Stage CD7-Targeted Lentiviral In Vivo CAR-T Platform
TPST - Tempest Secures Exclusive Option to License Clinical -Stage CD7-Targeted Lentiviral In Vivo CAR-T Platform
NEWS | Sep 15, 2026, 08:12 PM UTC
L
Tempest Therapeutics to present at H.C. Wainwright 28th conference
Tempest Therapeutics, Inc. (TPST) announced it will present at the H.C. Wainwright 28th Annual Global Investment Conference. The company said Matt Angel, Ph.D., is scheduled to present.
EQUITY | Sep 08, 2026, 12:37 PM UTC
L
TPST - Tempest to Present at the H.C. Wainwright 28th Annual Global Investment Conference
TPST - Tempest to Present at the H.C. Wainwright 28th Annual Global Investment Conference
EQUITY | Sep 08, 2026, 12:31 PM UTC
L
Tempest (TPST) reports Q2 2026 financial results and business update
Tempest (TPST) reports Second Quarter 2026 financial results and provides a business update, with no additional figures or guidance details included in the feed.
EARNINGS | Aug 13, 2026, 08:25 PM UTC
L
TPST - Tempest announces development collaboration with senlang Biotechnology for tpst-4003, a cd7-targeted next-generation in vivo Car-t Te
TPST - Tempest announces development collaboration with senlang Biotechnology for tpst-4003, a cd7-targeted next-generation in vivo Car-t Tempest Therapeutics - first patient dosing for tpst-4003 trial expected in Q4 202
GEOPOLITICS | Jul 21, 2026, 11:02 AM UTC
M
ADSK, TPST, ENR, AVO, PWRL: Insider Buys
Insiders purchase shares of ADSK, TPST, ENR, AVO, and PWRL in transactions over $100K
EQUITY | Jun 24, 2026, 09:58 AM UTC
M
Healthcare Stocks Move
Multiple healthcare stocks are moving in Tuesday's after-market session, with some rising and others falling
EQUITY | Jun 23, 2026, 09:09 PM UTC
L
TPST CEO Buys $500k
TPST CEO acquires $500k via purchase agreement
EQUITY | Jun 23, 2026, 09:02 PM UTC
L
TPST: CEO Buys Shares
Tempest Therapeutics CEO and President Angel Matthew P buys 231,482 shares at $2.16
EQUITY | Jun 23, 2026, 08:57 PM UTC